BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Virol. Mar 25, 2026; 15(1): 114321
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.114321
Figure 1
Figure 1 Management of patients with hepatitis c virus related cirrhosis in liver transplantation waiting list. DAA: Directly acting antiviral; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; LT: Liver transplantation; MELD: Model for end stage liver disease.
Figure 2
Figure 2 Management of hepatitis E virus infection in liver transplantation recipients. HEV: Hepatitis E virus; IgG: Immunoglobulin G; PEG-IFN: Pegylated-interferon; RBV: Ribavirin; IS: Immunosupression.
Figure 3
Figure 3 Management of cytomegalovirus infection in liver transplantation recipients. CMV: Cytomegalovirus.
Figure 4
Figure 4 Management of post-transplant lymphoproliferative disorders in liver transplant recipients. CBC: Complete blood cell count; CT: Computed tomography; EBV: Epstein-Barr virus; FDG-PET: Fluoro-2-deoxy-D-glucose positron emission tomography; GI: Gastrointestinal; HP: Histopathology; LDH: Lactate dehydrogenase; LT: Liver transplantation; MRI: Magnetic resonance imaging; PTLD: Post-transplant lymphoproliferative disorders.